AstraZeneca UK decides to terminate distribution agreement for Meronem

In India

AstraZeneca Pharma India has received a notice of termination from AstraZeneca UK, conveying its decision for termination of distribution agreement for Meronem (meropenem) in India. This is as a result of a global agreement by AstraZeneca PLC to sell the development and commercialisation rights to Pfizer Inc, of its late-stage small molecule antibiotics business.

Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalised patients.

Powered by Capital Market - Live News